The development of CRISPR–epigenome platforms, such as dCas9–DNMT3a fusion proteins, enables targeted methylation of ncRNA loci, reconstructing “epigenetic memory” and establishing long-term therapeutic reprogramming in HF (Qian and Liu, 2024). This evidence concerns the gene DNMT3A and hydrops fetalis.